Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SloveniaBack to Slovenia

Clinical trials in Maribor

29 clinical trials in Maribor, Slovenia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SloveniaOur site in SloveniaKlinicnaPreskusanja.si(opens in a new tab)
Maribor at a glance
29
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

29 trials in Maribor

Open in trial search

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Sjogren's syndrome

Recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Partial seizures

Recruiting

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Acute myocardial infarction+1

Recruiting

Study of Lower Blood Pressure Targets Using Noradrenaline in Patients with Heart Attack-Related Cardiogenic Shock

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Noradrenaline Tartrate
  • Sponsor:Amsterdam UMC Stichting

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Recruiting
Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Critical illness

Recruiting

Study of Epoetin Alfa for Critically Ill Patients with Traumatic Injury

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:University College Dublin

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Dementia Alzheimer's type

Not recruiting

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Slovenia

The busiest research cities in the country

All 18 cities in Slovenia

Clinical research in Maribor

What the registry says about research in the country

01 Neurological Disorders

Research focusing on breakthrough treatments for Multiple Sclerosis and neurodegenerative conditions, including evaluations of novel therapies like remibrutinib and ocrelizumab. Studies are examining treatment effectiveness for patients with various forms of MS.

  • Relapsing Multiple Sclerosis (RMS)
  • Early Alzheimer's Disease
  • Refractory Focal Onset Epilepsy

Innovative trials exploring cognitive improvement and disease progression reduction.

02 Autoimmune Conditions

Comprehensive studies evaluating treatments for Sjögren's Syndrome and other autoimmune disorders, with particular focus on systemic manifestations and long-term safety profiles.

  • IgA Nephropathy
  • Hidradenitis Suppurativa
  • Crohn's Disease

Trials aimed at developing targeted therapies for moderate to severe disease manifestations.

03 Oncology Research

Advanced clinical investigations in Non-Small Cell Lung Cancer and gynecological cancers, evaluating novel combination therapies and maintenance treatments.

  • Advanced Endometrial Cancer
  • Multiple Myeloma
  • PD-L1 High NSCLC

Focus on immunotherapy combinations and targeted treatment approaches.

04 Critical Care Medicine

Studies addressing acute medical conditions including cardiogenic shock and severe respiratory infections, with emphasis on improving patient outcomes.

  • Traumatic Injury
  • Community-Acquired Pneumonia
  • Acute Myocardial Infarction

Research aimed at reducing mortality and improving treatment protocols in critical care settings.

Back to SloveniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.